Literature DB >> 2277877

Quality adjusted survival analysis.

P P Glasziou1, R J Simes, R D Gelber.   

Abstract

We present a technique, quality adjusted survival analysis, for the analysis of controlled trials where patients may experience several health states which differ in their quality of life. When the data are censored, a survival analysis of the quality adjusted life years achieved may involve informative censoring, and produce biased estimates. To overcome this, we partition the survival curve; the resulting areas, which represent the mean time in each state, are multiplied by utility weights to provide an unbiased estimate of (restricted) quality adjusted survival. If the appropriate weights are in doubt, the results are best presented as a threshold analysis over the utility weights, allowing individual recommendation to be read from a simple graph. The certainty of the conclusions can be presented as confidence bands on the threshold line. The techniques are illustrated with a re-analysis of a large three-arm trial of adjuvant chemoendocrine therapy for stage II breast cancer in postmenopausal women. This shows that if the value of time spent in toxicity is greater than the time spent in relapse, we can be 95 per cent confident that chemoendocrine therapy is the preferred option.

Entities:  

Mesh:

Year:  1990        PMID: 2277877     DOI: 10.1002/sim.4780091106

Source DB:  PubMed          Journal:  Stat Med        ISSN: 0277-6715            Impact factor:   2.373


  57 in total

1.  Expressing estimators of expected quality adjusted survival as functions of Nelson-Aalen estimators.

Authors:  Y Huang; T A Louis
Journal:  Lifetime Data Anal       Date:  1999-09       Impact factor: 1.588

2.  Economic and quality-of-life aspects of treating small cell lung cancer.

Authors:  P Graham; J Boyages
Journal:  Pharmacoeconomics       Date:  1993-06       Impact factor: 4.981

3.  Meta-analysis and quality of evidence in the economic evaluation of drug trials.

Authors:  R J Simes; P P Glasziou
Journal:  Pharmacoeconomics       Date:  1992-04       Impact factor: 4.981

4.  Interpreting pharmacoeconomic and quality-of-life clinical trial data for use in therapeutics.

Authors:  M A Testa; W R Lenderking
Journal:  Pharmacoeconomics       Date:  1992-08       Impact factor: 4.981

5.  Nonparametric Benefit-Risk Assessment Using Marker Process in the Presence of a Terminal Event.

Authors:  Yifei Sun; Chiung-Yu Huang; Mei-Cheng Wang
Journal:  J Am Stat Assoc       Date:  2017-04-12       Impact factor: 5.033

6.  Implications of model misspecification in robust tests for recurrent events.

Authors:  J Boher; R J Cook
Journal:  Lifetime Data Anal       Date:  2006-03       Impact factor: 1.588

7.  Testing transition probability matrix of a multi-state model with censored data.

Authors:  Prabhanjan Narayanachar Tattar; H Jalikop H Vaman
Journal:  Lifetime Data Anal       Date:  2008-06       Impact factor: 1.588

8.  A semi-Markov multistate model for estimation of the mean quality-adjusted survival for non-progressive processes.

Authors:  Gisela Tunes-da-Silva; Antonio C Pedroso-de-Lima; Pranab K Sen
Journal:  Lifetime Data Anal       Date:  2008-12-10       Impact factor: 1.588

Review 9.  Systemic therapy in breast cancer: efficacy and cost utility.

Authors:  J F Corry; P E Lønning
Journal:  Pharmacoeconomics       Date:  1994-03       Impact factor: 4.981

10.  A utility assessment of oral and intravenous ganciclovir for the maintenance treatment of AIDS-related cytomegalovirus retinitis.

Authors:  E S Johnson; S D Sullivan; E Mozaffari; P C Langley; N J Bodsworth
Journal:  Pharmacoeconomics       Date:  1996-12       Impact factor: 4.981

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.